Selecting multimodal therapy for rhabdomyosarcoma

Expert Review of Anticancer Therapy

Volumn 10, Issue 8, 2010, Pages 1285-1301

  Sultan, Iyad ^a   Ferrari, Andrea ^b  

^a KING HUSSEIN CANCER CENTER   (Jordan)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

chemotherapy; multidisciplinary; pediatric; prognosis; radiotherapy; rhabdomyosarcoma; soft tissue sarcoma; stratification; surgery

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; IRINOTECAN; TOPOTECAN; VINCRISTINE;

AGE DISTRIBUTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CHILDHOOD CANCER; CLINICAL TRIAL; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; REVIEW; RHABDOMYOSARCOMA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; RHABDOMYOSARCOMA; TREATMENT OUTCOME;

EID: 77956238374     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.96     Document Type: Review

References (156)

1. Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update. Arch. Pathol. Lab. Med. 130(10), 1454-1465 (2006).
2. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 9 Regs Limited-Use, Nov 2008 Sub (1973-2006) - Linked To County Attributes - Total U.S., 1969-2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission.
3. Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J. Clin. Oncol. 27(20), 3391-3397 (2009).
4. Newton WA Jr, Gehan EA, Webber BL et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification - an Intergroup Rhabdomyosarcoma Study. Cancer 76(6), 1073-1085 (1995).
5. Raney RB, Anderson JR, Barr FG et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J. Pediatr. Hematol. Oncol. 23(4), 215-220 (2001).
6. Raney RB, Maurer HM, Anderson JR et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 5(1), 9-15 (2001).
7. Stevens MC, Rey A, Bouvet N et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology - SIOP Malignant Mesenchymal Tumor 89. J. Clin. Oncol. 23(12), 2618-2628 (2005).
8. Defachelles AS, Rey A, Oberlin O, Spooner D, Stevens MC. Treatment of nonmetastatic cranial parameningeal rhabdomyosarcoma in children younger than 3 years old: results from International Society of Pediatric Oncology studies MMT 89 and 95. J. Clin. Oncol. 27(8), 1310-1315 (2009).
9. Modritz D, Ladenstein R, Potschger U et al. Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study. Wien Klin. Wochenschr. 117(5-6), 196-209 (2005).
10. Dantonello TM, Int-Veen C, Harms D et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J. Clin. Oncol. 27(9), 1446-1455 (2009).
11. Bisogno G, De Rossi C, Gamboa Y et al. Improved survival for children with parameningeal rhabdomyosarcoma: results from the AIEOP Soft Tissue Sarcoma Committee. Pediatr. Blood Cancer 50(6), 1154-1158 (2008).
12. Cecchetto G, Carretto E, Bisogno G et al. Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: a report from the AIEOP Soft Tissue Sarcoma Committee. Pediatr. Blood Cancer 51(5), 593-597 (2008).
13. Crist WM, Garnsey L, Beltangady MS et al. Prognosis in children with rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Studies I and II. Intergroup Rhabdomyosarcoma Committee. J. Clin. Oncol. 8(3), 443-452 (1990).
14. Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist W. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr. Blood Cancer 42(1), 64-73 (2004).
15. Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on Intergroup Rhabdomyosarcoma Studies III and IV: the Children's Oncology Group. J. Clin. Oncol. 24(24), 3844-3851 (2006).
16. Neville HL, Andrassy RJ, Lobe TE et al. Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). J. Pediatr. Surg. 35(2), 317-321 (2000).
17. Rodary C, Gehan EA, Flamant F et al. Prognostic factors in 951 nonmetastatic rhabdomyosarcoma in children: a report from the International Rhabdomyosarcoma Workshop. Med. Pediatr. Oncol. 19(2), 89-95 (1991).
18. Rodary C, Rey A, Olive D et al. Prognostic factors in 281 children with nonmetastatic rhabdomyosarcoma (RMS) at diagnosis. Med. Pediatr. Oncol. 16(2), 71-77 (1988).
19. Koscielniak E, Harms D, Henze G et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J. Clin. Oncol. 17(12), 3706-3719 (1999).
20. Burke M, Anderson JR, Kao SC et al. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience. A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J. Clin. Oncol. 25(31), 4909-4913 (2007).
21. Ferrari A, Miceli R, Meazza C et al. Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. J. Clin. Oncol. 28(8), 1322-1328 (2010).
22. Ferrari A, Miceli R, Meazza C et al. Soft tissue sarcomas of childhood and adolescence: the prognostic role of tumor size in relation to patient body size. J. Clin. Oncol. 27(3), 371-376 (2009).
23. Loh WE Jr, Scrable HJ, Livanos E et al. Human chromosome 11 contains two different growth suppressor genes for embryonal rhabdomyosarcoma. Proc. Natl Acad. Sci. USA 89(5), 1755-1759 (1992).
24. Bridge JA, Liu J, Weibolt V et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study. Genes Chromosomes Cancer 27(4), 337-344 (2000).
25. Davicioni E, Anderson MJ, Finckenstein FG et al. Molecular classification of rhabdomyosarcoma - genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am. J. Pathol. 174(2), 550-564 (2009).
26. Barr FG, Smith LM, Lynch JC et al. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group. J. Mol. Diagn. 8(2), 202-208 (2006).
27. Sorensen PH, Lynch JC, Qualman SJ et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. J. Clin. Oncol. 20(11), 2672-2679 (2002).
28. Williamson D, Missiaglia E, de Reynies A et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J. Clin. Oncol. 28(13), 2151-2158 (2010).
29. Breitfeld PP, Meyer WH. Rhabdomyosarcoma: new windows of opportunity. Oncologist 10(7), 518-527 (2005).
30. Koscielniak E, Jurgens H, Winkler K et al. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study. Cancer 70(10), 2557-2567 (1992).
31. Meyer WH, Spunt SL. Soft tissue sarcomas of childhood. Cancer Treat. Rev. 30(3), 269-280 (2004).
32. Ruymann FB, Grovas AC. Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Invest. 18(3), 223-241 (2000).
33. Ferrari A, Casanova M. Current chemotherapeutic strategies for rhabdomyosarcoma. Expert Rev. Anticancer Ther. 5(2), 283-294 (2005).
34. Parham DM. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod. Pathol. 14(5), 506-514 (2001).
35. Mazzoleni S, Bisogno G, Garaventa A et al. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer 104(1), 183-190 (2005)
36. Pappo AS, Anderson JR, Crist WM et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J. Clin. Oncol. 17(11), 3487-3493 (1999).
37. Donaldson SS, Anderson JR. Rhabdomyosarcoma: many similarities, a few philosophical differences. J. Clin. Oncol. 23(12), 2586-2587 (2005).
38. Stevens MC. Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol. 6(2), 77-84 (2005).
39. Hays DM, Lawrence W Jr, Wharam M et al. Primary reexcision for patients with 'microscopic residual' tumor following initial excision of sarcomas of trunk and extremity sites. J. Pediatr. Surg. 24(1), 5-10 (1989).
40. Raney RB, Stoner JA, Walterhouse DO et al. Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study-IV, 1991-1997. Pediatr. Blood Cancer 42(7), 618-625 (2004).
41. Hays DM, Raney RB, Crist WM et al. Secondary surgical procedures to evaluate primary tumor status in patients with chemotherapy-responsive stage III and IV sarcomas: a report from the Intergroup Rhabdomyosarcoma Study. J. Pediatr. Surg. 25(10), 1100-1105 (1990).
42. Chui CH, Billups CA, Pappo AS, Rao BN, Spunt SL. Predictors of outcome in children and adolescents with rhabdomyosarcoma of the trunk - the St Jude Children's Research Hospital experience. J. Pediatr. Surg. 40(11), 1691-1695 (2005).
43. Arndt CA, Hammond S, Rodeberg D, Qualman S. Significance of persistent mature rhabdomyoblasts in bladder/ prostate rhabdomyosarcoma: results from IRS IV. J. Pediatr. Hematol. Oncol. 28(9), 563-567 (2006).
44. Oberlin O, Rey A, Anderson J et al. Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment - results of an international workshop. J. Clin. Oncol. 19(1), 197-204 (2001).
45. Buwalda J, Schouwenburg PF, Blank LE et al. A novel local treatment strategy for advanced stage head and neck rhabdomyosarcomas in children: results of the AMORE protocol. Eur. J. Cancer 39(11), 1594-1602 (2003).
46. Dall'Igna P, Bisogno G, Ferrari A et al. Primary transcrotal excision for paratesticular rhabdomyosarcoma: is hemiscrotectomy really mandatory? Cancer 97(8), 1981-1984 (2003).
47. Ferrari A, Bisogno G, Casanova M et al. Paratesticular rhabdomyosarcoma: report from the Italian and German Cooperative Group. J. Clin. Oncol. 20(2), 449-455 (2002).
48. Olive D, Flamant F, Zucker JM et al. Paraaortic lymphadenectomy is not necessary in the treatment of localized paratesticular rhabdomyosarcoma. Cancer 54(7), 1283-1287 (1984).
49. Stewart RJ, Martelli H, Oberlin O et al. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: Results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology. J. Clin. Oncol. 21(5), 793-798 (2003).
50. Wiener ES, Anderson JR, Ojimba JI et al. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin. Pediatr. Surg. 10(3), 146-152 (2001).
51. Wiener ES, Lawrence W, Hays D et al. Retroperitoneal node biopsy in paratesticular rhabdomyosarcoma. J. Pediatr. Surg. 29(2), 171-177 (1994).
52. Arndt C, Rodeberg D, Breitfeld PP, Raney RB, Ullrich F, Donaldson S. Does bladder preservation (as a surgical principle) lead to retaining bladder function in bladder/prostate rhabdomyosarcoma? Results from Intergroup Rhabdomyosarcoma Study IV. J. Urol. 171(6 Pt 1), 2396-2403 (2004).
53. Martelli H, Haie-Meder C, Branchereau S et al. Conservative surgery plus brachytherapy treatment for boys with prostate and/or bladder neck rhabdomyosarcoma: a single team experience. J. Pediatr. Surg. 44(1), 190-196 (2009).
54. Crist W, Gehan EA, Ragab AH et al. The Third Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol. 13(3), 610-630 (1995).
55. Crist WM, Anderson JR, Meza JL et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J. Clin. Oncol. 19(12), 3091-3102 (2001).
56. Flamant F, Rodary C, Rey A et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur. J. Cancer 34(7), 1050-1062 (1998).
57. Maurer HM, Beltangady M, Gehan EA et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 61(2), 209-220 (1988).
58. Wolden SL, Anderson JR, Crist WM et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Studies I to III. J. Clin. Oncol. 17(11), 3468-3475 (1999).
59. Schuck A, Mattke AC, Schmidt B et al. Group II rhabdomyosarcoma and rhabdomyosarcomalike tumors: is radiotherapy necessary? J. Clin. Oncol. 22(1), 143-149 (2004).
60. Viswanathan AN, Grier HE, Litman HJ et al. Outcome for children with group III rhabdomyosarcoma treated with or without radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 58(4), 1208-1214 (2004).
61. Wharam MD, Hanfelt JJ, Tefft MC et al. Radiation therapy for rhabdomyosarcoma: local failure risk for clinical group III patients on Intergroup Rhabdomyosarcoma Study II. Int. J. Radiat. Oncol. Biol. Phys. 38(4), 797-804 (1997).
62. Arndt CA, Donaldson SS, Anderson JR et al. What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract? Cancer 91(12), 2454-2468 (2001).
63. Maurer HM, Gehan EA, Beltangady M et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 71(5), 1904-1922 (1993).
64. Michalski JM, Meza J, Breneman JC et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int. J. Radiat. Oncol. Biol. Phys. 59(4), 1027-1038 (2004).
65. Raney RB, Meza J, Anderson JR et al. Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med. Pediatr. Oncol. 38(1), 22-32 (2002).
66. Meazza C, Ferrari A, Casanova M et al. Evolving treatment strategies for parameningeal rhabdomyosarcoma: the experience of the Istituto Nazionale Tumori of Milan. Head Neck 27(1), 49-57 (2005).
67. Combs SE, Behnisch W, Kulozik AE, Huber PE, Debus J, Schulz-Ertner D. Intensity modulated radiotherapy (IMRT) and fractionated stereotactic radiotherapy (FSRT) for children with head-and-neckrhabdomyosarcoma. BMC Cancer 7, 177 (2007).
68. Laskar S, Bahl G, Ann Muckaden M et al. Interstitial brachytherapy for childhood soft tissue sarcoma. Pediatr. Blood Cancer 49(5), 649-655 (2007).
69. McDonald MW, Esiashvili N, George BA et al. Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma. Int. J. Radiat. Oncol. Biol. Phys. 72(3), 884-891 (2008).
70. Curtis AE, Okcu MF, Chintagumpala M, Teh BS, Paulino AC. Local control after intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int. J. Radiat. Oncol. Biol. Phys. 73(1), 173-177 (2009).
71. Donaldson SS, Asmar L, Breneman J et al. Hyperfractionated radiation in children with rhabdomyosarcoma - results of an Intergroup Rhabdomyosarcoma Pilot Study. Int. J. Radiat. Oncol. Biol. Phys. 32(4), 903-911 (1995).
72. Mandell LR, Ghavimi F, Exelby P, Fuks Z. Preliminary results of alternating combination chemotherapy (CT) and hyperfractionated radiotherapy (HART) in advanced rhabdomyosarcoma (RMS). Int. J. Radiat. Oncol. Biol. Phys. 15(1), 197-203 (1988).
73. Heyn R, Holland R, Joo P et al. Treatment of rhabdomyosarcoma in children with surgery, radiotherapy and chemotherapy. Med. Pediatr. Oncol. 3(1), 21-32 (1977).
74. Carli M, Pastore G, Perilongo G et al. Tumor response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma. J. Clin. Oncol. 6(4), 654-658 (1988).
75. Spunt SL, Smith LM, Ruymann FB et al. Cyclophosphamide dose intensification during induction therapy for intermediaterisk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Clin. Cancer Res. 10(18 Pt 1), 6072-6079 (2004).
76. Treuner J, Koscielniak E, Keim M. Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas. Cancer Chemother. Pharmacol. 24(Suppl. 1), S48-S50 (1989).
77. Arndt CA, Stoner JA, Hawkins DS et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803. J. Clin. Oncol. 27(31), 5182-5188 (2009).
78. Mascarenhas L, Lyden ER, Breitfeld PP et al. Randomized Phase II window study of two schedules of irinotecan (CPT-11) and vincristine (VCR) in rhabdomyosarcoma (RMS) at first relapse/disease progression. J. Clin. Oncol. 26(15 Suppl.) (2008) (Abstract 10013).
79. Stevens M, Rey A, Bouvet N. SIOP MMT95: Intensified (6 drug) versus standard (IVA) chemotherapy for high risk nonmetastatic rhabdomyosarcoma (RMS). J. Clin. Oncol. 15, 802s (2004) (Abstract 8515).
80. Breitfeld PP, Lyden E, Raney RB et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J. Pediatr. Hematol. Oncol. 23(4), 225-233 (2001).
81. Klingebiel T, Boos J, Beske F et al. nTreatment of children with metastatic soft tissue sarcoma with oral maintenance compared with high dose chemotherapy: report of the HD CWS-96 trial. Pediatr. Blood Cancer 50(4), 739-745 (2008).
82. Lager JJ, Lyden ER, Anderson JR, Pappo AS, Meyer WH, Breitfeld PP. Pooled analysis of Phase II window studies inn children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J. Clin. Oncol. 24(21), 3415-3422 (2006).
83. Smith MA, Anderson B. Phase II window studies: 10 years of experience and counting. J. Pediatr. Hematol. Oncol. 23(6), 334-337 (2001).
84. Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ, Wharam MD, Meyer WH. Efficacy of topotecan and cyclophosphamide given in a Phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. J. Clin. Oncol. 22(8), 1398-1403 (2004).
85. Blaney SM, Needle MN, Gillespie A et al. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin. Cancer Res. 4(2), 357-360 (1998).
86. Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group Phase II study. J. Pediatr. Hematol. Oncol. 20(4), 315-318 (1998).
87. Pappo AS, Lyden E, Breneman J et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol. 19(1), 213-219 (2001).
88. Saylors RL 3rd, Stine KC, Sullivan J et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II study. J. Clin. Oncol. 19(15), 3463-3469 (2001).
89. Rodriguez-Galindo C, Crews KR, Stewart CF et al. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemother. Pharmacol. 57(1), 15-24 (2006).
90. Meazza C, Casanova M, Zaffignani E et al. Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/ refractory rhabdomyosarcoma. Med. Oncol. 26(1), 67-72 (2009).
91. Houghton PJ, Cheshire PJ, Hallman JD 2nd et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. 36(5), 393-403 (1995).
92. Vassal G, Terrier-Lacombe MJ, Bissery MC et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br. J. Cancer 74(4), 537-545 (1996).
93. Bisogno G, Riccardi R, Ruggiero A et al. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 106(3), 703-707 (2006).
94. Pappo AS, Lyden E, Breitfeld P et al. Two consecutive Phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J. Clin. Oncol. 25(4), 362-369 (2007).
95. Casey DA, Wexler LH, Merchant MS et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr. Blood Cancer 53(6), 1029-1034 (2009).
96. Wagner LM, McAllister N, Goldsby RE et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr. Blood Cancer 48(2), 132-139 (2007).
97. Levy AS, Meyers PA, Wexler LH et al. Phase 1 and pharmacokinetic study of oncurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. Cancer 115(1), 207-216 (2009).
98. McGregor LM, Spunt SL, Furman WL et al. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer 115(8), 1765-1775 (2009).
99. Furman WL, Crews KR, Billups C et al. Cefixime allows greater dose escalation of oral irinotecan: a Phase I study in pediatric patients with refractory solid tumors. J. Clin. Oncol. 24(4), 563-570 (2006).
100. Ferraldeschi R, Minchell LJ, Roberts SA et al. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics 10(5), 733-739 (2009).
101. Furman WL, Navid F, Daw NC et al. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J. Clin. Oncol. 27(27), 4599-4604 (2009).
102. Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F, Beretta G. Phase I and preliminary Phase II evaluation of adriamycin (NSC 123127). Cancer Res. 30(10), 2572-2582 (1970).
103. O'Bryan RM, Luce JK, Talley RW, Gottlieb JA, Baker LH, Bonadonna G. Phase II evaluation of adriamycin in human neoplasia. Cancer 32(1), 1-8 (1973).
104. Tan C, Etcubanas E, Wollner N et al. Adriamycin - an antitumor antibiotic in the treatment of neoplastic diseases. Cancer 32(1), 9-17 (1973).
105. Bergeron C, Thiesse P, Rey A et al. Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease. Eur. J. Cancer 44(3), 427-431 (2008).
106. Pratt CB, Crom DB. Cisplatin and doxorubicin for locally recurrent and metastatic childhood rhabdomyosarcoma. Chemioterapia 3(4), 207-210 (1984).
107. Etcubanas E, Horowitz M, Vogel R. Combination of dacarbazine and doxorubicin in the treatment of childhood rhabdomyosarcoma. Cancer Treat. Rep. 69(9), 999-1000 (1985).
108. Womer RB. The Intergroup Rhabdomyosarcoma Studies come of age. Cancer 71(5), 1719-1721 (1993).
109. Arndt CA, Hawkins DS, Meyer WH, Sencer bSF, Neglia JP, Anderson JR. Comparison of results of a pilot study of alternating vincristine/doxorubicin/ cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group. Pediatr. Blood Cancer 50(1), 33-36 (2006).
110. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J. Natl Cancer Inst. 83(20), 1460-1470 (1991).
111. Bisogno G, Ferrari A, Bergeron C et al. The IVADo regimen - a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study on behalf of the European pediatric Soft tissue sarcoma Study Group. Cancer 103(8), 1719-1724 (2005).
112. Ferrari A, Casanova M, Bisogno G et al. Rhabdomyosarcoma in infants younger than one year old: a report from the Italian Cooperative Group. Cancer 97(10), 2597-2604 (2003).
113. Stiller CA, Stevens MC, Magnani C, Corazziari I. Survival of children with soft-tissue sarcoma in Europe since 1978: results from the EUROCARE study. Eur. J. Cancer 37(6), 767-774 (2001).
114. La Quaglia MP, Heller G, Ghavimi F et al. The effect of age at diagnosis on outcome in rhabdomyosarcoma. Cancer 73(1), 109-117 (1994).
115. Arndt C, Hawkins D, Anderson JR, Breitfeld P, Womer R, Meyer W. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J. Clin. Oncol. 22(10), 1894-1901 (2004).
116. Carli M, Colombatti R, Oberlin O et al. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J. Clin. Oncol. 22(23), 4787-4794 (2004).
117. Koscielniak E, Rodary C, Flamant F et al. Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis. Med. Pediatr. Oncol. 20(3), 209-214 (1992).
118. Oberlin O, Rey A, Lyden E et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J. Clin. Oncol. 26(14), 2384-2389 (2008).
119. Koscielniak E, Klingebiel TH, Peters C et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant. 19(3), 227-231 (1997).
120. Carli M, Colombatti R, Oberlin O et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J. Clin. Oncol. 17(9), 2796-2803 (1999).
121. Weigel BJ, Breitfeld PP, Hawkins D, Crist WM, Baker KS. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J. Pediatr. Hematol. Oncol. 23(5), 272-276 (2001).
122. Raney RB Jr, Tefft M, Maurer HM et al. Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)-I. Cancer 62(7), 1257-1266 (1988).
123. Bisogno G, Ferrari A, Prete A et al. Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. Eur. J. Cancer 45(17), 3035-3041 (2009).
124. Mackall CL, Helman LJ. High-dose chemotherapy for rhabdomyosarcoma: where do we go from here. J. Pediatr. Hematol. Oncol. 23(5), 266-267 (2001).
125. Meyers PA. High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr. Opin. Oncol. 16(2), 120-125 (2004).
126. Donker AE, Hoogerbrugge PM, nMavinkurve-Groothuis AM et al. Metastatic rhabdomyosarcoma cured after chemotherapy and allogeneic SCT. Bone Marrow Transplant. 43(2), 179-180 (2009).
127. Womer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur. J. Cancer 36(1), 87-94 (2000).
128. Weigel B, Lyden E, Anderson JR et al. Early results from Children's Oncology Group (COG) ARST0431: intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS). J. Clin. Oncol. 28(7 Suppl.) (2010)(Abstract 9503).
129. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354(2), 166-178 (2006).
130. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105(8), 1045-1047 (2000).
131. Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose antiangiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann. Oncol. 13(1), 12-15 (2002).
132. Casanova M, Ferrari A, Bisogno G et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 101(7), 1664-1671 (2004).
133. Kuttesch JF Jr, Krailo MD, Madden T, Johansen M, Bleyer A. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study. Pediatr. Blood Cancer 53(4), 590-593 (2009).
134. Casanova M, Ferrari A, Spreafico F et al. Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 94(12), 3263-3268 (2002).
135. Klement G, Baruchel S, Rak J et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105(8), R15-R24 (2000).
136. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur. J. Cancer 29A(9), 1320-1324 (1993).
137. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. The effect of vinca alkaloids on tumour blood flow. Adv. Exp. Med. Biol. 345, 417-422 (1994).
138. Hill SA, Sampson LE, Chaplin DJ. Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int. J. Cancer 63(1), 119-123 (1995).
139. Ma J, Waxman DJ. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol. Cancer Ther. 7(1), 79-89 (2008).
140. Linden O, Greiff L, Wahlberg P, Vinge E, Kjellen E. Chemorefractory rhabdomyosarcoma treated with radiotherapy, bevacizumab, statins and surgery and maintenance with bevacizumab and chemotherapy. Onkologie 31(7), 391-393 (2008).
141. Benesch M, Windelberg M, Sauseng W et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann. Oncol. 19(4), 807-813 (2008).
142. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 12(8), 1007-1018 (2007).
143. Houghton PJ, Morton CL, Kolb EA et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr. Blood Cancer 50(4), 799-805 (2008).
144. Mita MM, Mita AC, Chu QS et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J. Clin. Oncol. 26(3), 361-367 (2008).
145. Buckner JC, Forouzesh B, Erlichman C et al. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest. New Drugs 28(3), 334-342 (2009).
146. Dancey JE, Curiel R, Purvis J. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin. Oncol. 36(Suppl. 3), S46-S58 (2009).
147. Stock C, Zaccagnini M, Schulze M, Teber D, Rassweiler JJ. Temsirolimus. Recent Results Cancer Res. 184, 189-197 (2010).
148. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 195(2), 127-137 (2003).
149. Kolb EA, Gorlick R, Houghton PJ et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr. Blood Cancer 50(6), 1190-1197 (2008).
150. Malempati S, Weigel B, Ingle AM et al. A Phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: a Children's Oncology Group Phase I Consortium study. J. Clin. Oncol. 27(15 Suppl.) (2009) (Abstract 10013).
151. Driman D, Thorner PS, Greenberg ML, Chilton-MacNeill S, Squire J. MYCN gene amplification in rhabdomyosarcoma. Cancer 73(8), 2231-2237 (1994).
152. Forus A, Florenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O. Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Differ. 4(12), 1065-1070 (1993).
153. Ablett S, Doz F, Morland B, Vassal G. European collaboration in trials of new agents for children with cancer. Eur. J. Cancer 40(12), 1886-1892 (2004).
154. Houghton PJ, Adamson PC, Blaney S et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin. Cancer Res. 8(12), 3646-3657 (2002).
155. Gallego S, Llort A, Roma J, Sabado C, Gros L, de Toledo JS. Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay. J. Cancer Res. Clin. Oncol. 132(6), 356-362 (2006).
156. Sartori F, Alaggio R, Zanazzo G et al. Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers. Cancer 106(8), 1766-1775 (2006).